Cargando…

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens

Critical evaluation of how and when to include anthracyclines in preoperative chemotherapy is becoming more relevant in an era when the molecular genetic approach not only allows for the development of biologically targeted therapeutics, but also implies the ability to select the patients likely to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibragimova, M. K., Kravtsova, E. A., Tsyganov, M. M., Litviakov, N. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	A.I. Gordeyev 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615187/ https://www.ncbi.nlm.nih.gov/pubmed/37908774 http://dx.doi.org/10.32607/actanaturae.20377

Ejemplares similares

Whole Transcriptome Analysis of Breast Cancer Tumors during Neoadjuvant Chemotherapy: Association with Hematogenous Metastasis
por: Ibragimova, Marina K., et al.
Publicado: (2022)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Ibragimova, Marina K., et al.
Publicado: (2021)

Organ-Specificity of Breast Cancer Metastasis
por: Ibragimova, Marina K., et al.
Publicado: (2023)

Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy
por: Litviakov, Nikolai V., et al.
Publicado: (2016)

Tumour Stem Cells in Breast Cancer
por: Ibragimova, Marina, et al.
Publicado: (2022)

Amplifications of Stemness Gene Loci—New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study
por: Litviakov, Nikolai V., et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
por: de Pinho, Inês Soares, et al.
Publicado: (2023)

DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
por: Sigin, Vladimir O., et al.
Publicado: (2023)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
por: Jiang, Cui, et al.
Publicado: (2019)

Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study
por: Lu, Hang, et al.
Publicado: (2023)

Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression
por: Denisov, Evgeny V., et al.
Publicado: (2014)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

A pharmacophore‐based classification better predicts the outcomes of HER2‐negative breast cancer patients receiving the anthracycline‐ and/or taxane‐based neoadjuvant chemotherapy
por: Li, Xuan, et al.
Publicado: (2021)

WNT-Conditioned Mechanism of Exit from Postchemotherapy Shock of Differentiated Tumour Cells
por: Tsydenova, Irina A., et al.
Publicado: (2023)

DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer
por: Sigin, Vladimir O., et al.
Publicado: (2020)

The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients
por: Ding, Yuqin, et al.
Publicado: (2023)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Human papillomavirus and prostate cancer: systematic review and meta-analysis
por: Tsydenova, Irina A., et al.
Publicado: (2023)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Amplification of Stem Genes: New Potential Metastatic Makers in Patients with an Early Form of Breast Cancer
por: Tsyganov, Matvey M., et al.
Publicado: (2019)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
por: Susini, Tommaso, et al.
Publicado: (2014)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
por: Lucas, Mairi W, et al.
Publicado: (2022)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
por: Chen, Xiaosong, et al.
Publicado: (2016)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen
por: Dong, Zhaoying, et al.
Publicado: (2021)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis
por: Lobefaro, Riccardo, et al.
Publicado: (2020)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

A multifactorial ‘Consensus Signature’ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer
por: Turner, Natalie, et al.
Publicado: (2015)

Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
por: Tsyganov, Matvey M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bhf3r7ca8urecao2k0kdi790s0